It is suggested that only ‘hot’ tumours could be interfered by a single agent of checkpoint inhibitors by evidence from the preclinical and clinical trials, that is, ICIs could not work without the infiltration of CD8+ T cells [80,81]. The gene discussed is CD8A; the disease is neoplasm.